Graft-versus-host disease/ Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
| Autor: | Massenkeil, G., Rackwitz, S., Genvresse, I., Rosen, O., Dorken, B., Arnold, R. |
|---|---|
| Zdroj: | Bone Marrow Transplantation. 12/15/2002, Vol. 30 Issue 12, p899. 5p. 3 Charts, 2 Graphs. |
| Databáze: | Academic Search Ultimate |
| Externí odkaz: |
|